logo
Plus   Neg
Share
Email

MorphoSys Says Primary Goal Of Re-MIND Study Has Been Met

MorphoSys AG (MOR) Tuesday said the primary endpoint was met of a real-world data study demonstrating clinical superiority of the combination of tafasitamab and lenalidomide compared to lenalidomide alone.

According to the company, the study collected data from 490 non-transplant eligible patients with relapsed/ refractory diffuse large B cell lymphoma who had received lenalidomide monotherapy in the U.S. and the EU in a real-world setting.

As a result, 76 eligible patients were identified and matched 1:1 to 76 of 80 L-MIND patients based on important baseline characteristics.

The primary endpoint of the study has been met and shows a statistically significant superior best ORR of the tafasitamab/lenalidomide combination compared to lenalidomide monotherapy.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Beginning July 6, Google plans to reopen offices in more cities, which were closed following the coronavirus pandemic-related lockdowns across the globe, Chief Executive Officer Sundar Pichai told employees in an email. However, the search giant still expects and encourages most Googlers to largely work from home for the rest of 2020. For those working from home, the company offered an allowance. Bristol Myers Squibb (BMY) announced Wednesday that the European Commission (EC) has approved Zeposia (ozanimod) for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features. With the EC marketing authorization,... Off-price retailer Tuesday Morning Corp. (TUES) on Wednesday filed voluntary petitions for protection under Chapter 11 of the Bankruptcy Code in the U. S. Bankruptcy Court for the Northern District of Texas, Dallas Division. It plans to emerge as a stronger company by early fall 2020. The company...
Follow RTT